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Un
pêBACKGROUND After percutaneous coronary intervention (PCI) for non–ST-segment elevation myocardial infarction
(NSTEMI), treatment with a P2Y12 antagonist with aspirin is recommended for 1 year.
OBJECTIVES The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but
it is unknown if administration before the start of PCI is beneﬁcial.
METHODS In the randomized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary
intervention Or as pre-treatment At the time of diagnosis in patients with non–ST-segment elevation myocardial
infarction) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treatment
with prasugrel (30-mg loading dose), and 1,376 received placebo. At the time of PCI, patients who received pre-
treatment with prasugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a
60-mg loading dose of prasugrel. Primary efﬁcacy was a composite of cardiovascular death, myocardial infarction, stroke,
urgent revascularization, or glycoprotein IIb/IIIa bailout through 7 days from randomization. Investigators captured the
presence of thrombus on initial angiography and during PCI.
RESULTS The incidence of the primary endpoint through 7 days from randomization in the pre-treatment group versus
the no pre-treatment group was 13.1% versus 13.1% (p ¼ 0.93). Pre-treatment with prasugrel was not associated with
decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3-fold higher
incidence of the primary endpoint than patients without thrombus. There was no impact of pre-treatment with prasugrel
on the presence of thrombus before PCI or on occurrence of stent thrombosis after PCI. There was a 3-fold increase in all
non–coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleeding and a 6-fold increase in
non–coronary artery bypass graft life-threatening bleeding with pre-treatment with prasugrel; the same trends persisted
in patients who had radial or femoral access even with use of a closure device.
CONCLUSIONS These ﬁndings support deferring treatment with prasugrel until a decision is made about revasculari-
zation in patients with NSTEMI undergoing angiography within 48 h of admission. (A Comparison of prasugrel at the time
of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non—ST-segment
elevation myocardial infarction [ACCOAST]; NCT01015287) (J Am Coll Cardiol 2014;64:2563–71) © 2014 by the
American College of Cardiology Foundation.m the *ACTION Study Group, Institut de Cardiologie, UPMC Université Paris 6, INSERM UMRS-1166 Paris, Centre Hospitalier
iversitaire Pitié-Salpêtri _ere (AP-HP), Paris, France; yACTION Study Group, SMUR, Centre Hospitalier Universitaire Pitié-Sal-
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2565Syndrome) trials, leading to a class III recommendation
for pre-treatment with GP inhibitors in patients with
NSTE-ACS (1,2). The deleterious effects of pre-
treatment were also shown with clopidogrel in ran-
domized studies evaluating stable or stabilized
patients, leading to a class III recommendation for pre-
treatment with clopidogrel in these patients (3–6). No
randomized studies have evaluated routine pre-
treatment versus no pre-treatment with clopidogrel
or ticagrelor and invasive management in patients
with NSTE-ACS. In contrast, pre-treatment with pra-
sugrel was evaluated with patients with NSTE-ACS
scheduled to undergo catheterization in the random-
ized, double-blind ACCOAST (A Comparison of prasu-
grel at the time of percutaneous Coronary intervention
Or as pre-treatment At the time of diagnosis in patients
with non–ST-segment elevation myocardial infarc-
tion) trial, which revealed no additional efﬁcacy
beneﬁt with routine pre-treatment with prasugrel
compared with selective use of prasugrel at the time of
PCI but showed an increase in the rate of major
bleeding complications (7).
Intracoronary thrombus and thrombotic complica-
tions during PCI, in particular in patients with acute
coronary syndrome, have been a concern and have
led to the concept of pre-treatment with clopidogrel,
a drug with a delayed onset of action (8). Although
this strategy makes sense for patients undergoing
PCI, it was never demonstrated in patients with
NSTE-ACS who were invasively managed within 48 h
of admission, as performed in contemporary practice.
The ACCOAST-PCI study was a unique opportunity to
evaluate this concept in the modern era, in which
patients have rapid access to the catheterization
laboratory, frequent radial access, and access to drug-
eluting stents with modern pharmacological therapy,
including prasugrel.
METHODS
PARTICIPANTS. The ACCOAST-PCI study prospec-
tively evaluated 2,770 patients undergoing PCI who
were randomized to double-blind therapy with pra-
sugrel or placebo at 171 centers in 19 countries (7). The
inclusion and exclusion criteria for the ACCOAST trial
have been described previously (7,9). Brieﬂy, patients
were eligible for inclusion if they had a diagnosis of
NSTE-ACS with an elevated troponin level. Randomi-
zation was to take place as soon as possible after
diagnosis and before the patients received a loading
dose of clopidogrel or any dose of prasugrel or tica-
grelor. Patients were to be scheduled to undergo
coronary angiography within 2 to 48 h from randomi-
zation. The ACCOAST study design pre-speciﬁed theprospective capture on a speciﬁc part of the case report
form and the presence of thrombus during the proce-
dure, and additional analyses were performed in rela-
tionship to clinical outcomes.
PROCEDURES. In addition to aspirin, patients were
randomly assigned to receive either prasugrel or
matching placebo once admitted to the study site
with a diagnosis of non–ST-segment elevation
myocardial infarction (NSTEMI). In the pre-treatment
arm, patients received a 30-mg loading dose of pra-
sugrel and an additional 30-mg dose of prasugrel at
the time of PCI once angiography conﬁrmed the
indication for PCI. In the no pre-treatment arm, the
approved 60-mg loading dose of prasugrel was
administered after angiography at the time of PCI.
The ﬁrst open-label maintenance dose of prasugrel
was administered 18 to 24 h after PCI. Patients
received a 10-mg daily maintenance dose of prasugrel
in combination with aspirin through the follow-up
visit at 30 days. In patients who were 75 years of age
or older and/or had body weight <60 kg, a 5-mg daily
maintenance dose of prasugrel was administered.
We routinely screened for periprocedural increases
in cardiac enzyme concentrations every 8 h over the
ﬁrst 24 h after PCI. Deﬁnitions of myocardial infarction
used creatine kinase or creatine kinase-myocardial
bands and depended on the clinical timing of the
event in relation to the timing of the index event and
PCI procedures (9). The deﬁnition of urgent revascu-
larization was driven by recurrent signs of ischemia
occurring after completion of PCI, leading to a new
emergent revascularization (PCI or CABG surgery) of
either the vessel dilated at the initial procedure or a
vessel not initially dilated. The unplanned use of a GP
IIb/IIIa inhibitor while waiting for coronary angiog-
raphy/PCI, during PCI, or within 24 h after PCI was
considered bailout. Investigators documented plan-
ned use of a GP IIb/IIIa inhibitor once randomization
occurred or before PCI, and this was not considered a
GP IIb/IIIa inhibitor bailout endpoint. If Thrombolysis
In Myocardial Infarction (TIMI) ﬂow grade 0 to 1 was
identiﬁed during initial coronary angiography and
before PCI that required use of a GP IIb/IIIa inhibitor, a
GP IIb/IIIa inhibitor bailout endpoint was reported.
Reasons for use of GP IIb/IIIa inhibitor bailout were
recorded by the sites, and all cases of GP IIb/IIIa in-
hibitor bailout were adjudicated.
The primary endpointwas time toﬁrst occurrence of
cardiovascular death, myocardial infarction, stroke,
urgent revascularization, or GP IIb/IIIa inhibitor
bailout through 7 days from randomization. Safety
endpoints of TIMI major and minor bleeding were
evaluated as not related to CABG surgery and all
bleeding. Bleeding complications also were
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of Enoxaparin in PCI) deﬁnitions (9). An independent
endpoint adjudication committee adjudicated the
endpoints.
STATISTICAL CONSIDERATIONS. Comparisons of
efﬁcacy were performed on the basis of time to ﬁrst
event, according to intention-to-treat principle
(Online Appendix). Safety analyses were performed
on all patients who took at least one dose of study
drug. Primary efﬁcacy analysis was on the basis of
time from randomization to the ﬁrst occurrence of
the primary composite endpoint on the basis of a 2-
sided log-rank test. Time-to-event analyses for ef-
ﬁcacy and safety outcomes were performed through
7 and 30 days from randomization. Rates are
expressed as Kaplan-Meier estimates. An estimated
hazard ratio (HR) and 95% conﬁdence interval (CI)
were obtained from a Cox proportional hazards
model, and a 2-sided p value was obtained by the
log-rank test. A p value for efﬁcacy and safety was
considered statistically signiﬁcant when <0.05.FIGURE 1 Patient Flow
Intention 
popula
N=40
Pre-treatment
Coronary
Angiography
Day 7 
PCI only
N=1394
Day 30
PCI only
N=1389
CABG only N=121
MM N=516
PCI+CABG N=6
CABG only N=157
MM N=476
PCI+CABG N=15
A total of 4,033 patients were randomized in the ACCOAST study. A tot
and 1,376 patients in the no pre-treatment group underwent PCI. CABG
PCI ¼ percutaneous coronary intervention.Comparisons between patients with and without
thrombus on angiography were performed for efﬁ-
cacy outcomes. Additionally, a multivariate step-
wise Cox proportional hazards model was
performed for the primary efﬁcacy outcome and
TIMI major or minor bleeding to investigate which
characteristics were independently associated with
these outcomes.
RESULTS
DEMOGRAPHIC CHARACTERISTICS. Overall, 2,770
of the 4,033 patients (68.7%) in the ACCOAST trial
underwent PCI through 7 days from randomization.
Of these, 1,394 patients were assigned to pre-
treatment with prasugrel and 1,376 patients were
assigned to placebo at baseline. No patients were lost
to follow-up (Figure 1). The median delay between
randomization and PCI was 4.25 h. The 2 groups were
balanced with respect to baseline characteristics
(Online Table 1). By study design, all patients had an
increase in troponin level at randomization; 33% ofto treat
tion
33 
No Pre-treatment
Coronary
Angiography
Day 7 
PCI only
N=1376
Day 30
PCI only
N=1372
CABG only N=117
MM N=498
PCI+CABG N=5
N=157CABG only
MM N=456
PCI+CABG N=11
al of 1,394 patients in the pre-treatment group underwent PCI,
¼ coronary artery bypass graft; MM ¼ medical management;
TABLE 1 Efﬁcacy Endpoints Through 7 Days and 30 Days
Endpoint
Pre-Treatment
(n ¼ 1,394)
No Pre-Treatment
(n ¼ 1,376) HR (95% CI)* p Value†
7 days
CVD, MI, stroke, UR, or GP
IIb/IIIa inhibitor bailout
183 (13.1) 180 (13.1) 1.01 (0.82–1.24) 0.93
CVD, MI, or stroke 118 (8.5) 115 (8.4) 1.01 (0.78–1.31) 0.92
Death
All cause 4 (0.29) 4 (0.29) NE NE
CV 4 (0.29) 4 (0.29) NE NE
MI 114 (8.2) 108 (7.9) 1.05 (0.80–1.36) 0.75
Stroke 3 (0.22) 5 (0.36) NE NE
UR 18 (1.3) 23 (1.7) 0.77 (0.42–1.43) 0.41
GP IIb/IIIa inhibitor bailout 72 (5.2) 76 (5.5) 0.94 (0.68–1.30) 0.70
Deﬁnite or probable stent
thrombosis
1 (0.07) 3 (0.22) NE NE
30 days
CVD, MI, stroke, UR, or GP
IIb/IIIa inhibitor bailout
196 (14.1) 189 (13.8) 1.03 (0.84–1.26) 0.77
CVD, MI, or stroke 128 (9.2) 121 (8.8) 1.05 (0.82–1.34) 0.72
Death
All cause 11 (0.79) 11 (0.80) 0.96 (0.42–2.23) 0.92
CV 10 (0.72) 11 (0.80) 0.90 (0.38–2.12) 0.81
MI 118 (8.5) 111 (8.1) 1.05 (0.81–1.36) 0.70
Stroke 6 (0.43) 8 (0.58) 0.74 (0.26–2.13) 0.58
UR 26 (1.9) 28 (2.0) 0.92 (0.54–1.57) 0.75
GP IIb/IIIa inhibitor bailout 73 (5.3) 77 (5.6) 0.94 (0.68–1.29) 0.70
Deﬁnite or probable stent
thrombosis
2 (0.14) 5 (0.36) NE NE
Values for pre-treatment and no pre-treatment are n (%). *HRs and 2-sided 95% CIs are from a Cox proportional
hazards model with treatment as a ﬁxed effect. †2-sided p value on the basis of the log-rank test. Event rates are
raw percents.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; CVD ¼ cardiovascular death; GP ¼ glycoprotein; HR ¼ hazard
ratio; MI ¼ myocardial infarction; NE ¼ not evaluable; UR ¼ urgent revascularization.
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2567patients in both the prasugrel pre-treatment group
and no prasugrel pre-treatment group had initial
troponin levels $3 and <10 times the upper limit of
normal, and 51% of patients in both the prasugrel pre-
treatment group and no prasugrel pre-treatment
group had initial troponin levels $10 times the
upper limit of normal. Radial access was preferred in
43% of the PCI cohort. Among the patients who had
femoral access, a closure device was used in 40%.
The characteristics reﬂect a population that was
enrolled before coronary angiography; 4% had left
main PCI, 38% had multivessel PCI, 10% had dilation
of the 3 vessels, and 13% had long lesions, deﬁned as
more than 30 mm of stents. Drug-eluting stents were
used most of the time. Importantly, a thrombus was
angiographically noted before the start of PCI in
20% and 22% of patients with and without pre-
treatment with prasugrel, respectively (p ¼ 0.21).
The preferred anticoagulants were unfractionated
and low-molecular-weight heparins. Planned and
unplanned GP IIb/IIIa inhibitor therapy was used in
15% of patients, with only 5.2% in the prasugrel pre-
treatment group and 5.5% in the no prasugrel pre-
treatment group in bailout situations (not signiﬁcant
between groups). The duration of the PCI procedure
was similar in both groups.
OUTCOMES. The incidence of the primary endpoint
through 7 days from randomization was not different
between the prasugrel pre-treatment group and the
no prasugrel pre-treatment group (13.1% vs. 13.1%;
p ¼ 0.93) (Table 1). The main secondary endpoint
of cardiovascular death, myocardial infarction, or
stroke did not differ between the 2 groups (Central
Illustration, Table 1). Pre-treatment with prasugrel
was not associated with a decrease in any ischemic
event, including total mortality and stent thrombosis
(Table 1).
Bailout use of GP IIb/IIIa inhibitors was infrequent
(5% of patients) and did not differ between the 2
randomized groups (Table 1). Four of those 10
patients received GP IIb/IIIa inhibitors because of a
slow ﬂow before PCI was started, and the other 6
patients received GP IIb/IIIa inhibitors because of a
slow ﬂow or another complication during PCI. There
was no difference between the prasugrel pre-
treatment group and the no prasugrel pre-treatment
group regarding the use of GP IIb/IIIa inhibitors
either before or during PCI. The reasons for bailout
use of GP IIb/IIIa inhibitors are reported in Online
Table 2.
The baseline characteristics of patients with and
without thrombus on angiography are shown in
Online Table 3 and do not appear to differ. However,patients who had thrombus on angiography had a
3-fold higher incidence of 7-day and 30-day primary
endpoints than patients without thrombus on angi-
ography (Online Table 4). Surprisingly, there was no
impact on the rate of deﬁnite or probable stent
thrombosis in patients with thrombosis seen on
angiography versus patients with thrombus not seen
on angiography (Online Table 4). The results of the
multivariate analysis indicated that thrombus on
angiography was highly predictive of the primary
efﬁcacy outcomes (HR: 2.61 [95% CI: 2.09 to 3.25];
p < 0.001), adjusting for all other known signiﬁcant
predictors. Additional signiﬁcant predictors included
length of procedure (HR: 1.88 [95% CI: 1.49 to 2.36];
p < 0.001), number of lesions (HR: 1.24 [95% CI: 1.10
to 1.39]; p < 0.001), maximum length of stent (HR:
1.19 [95% CI: 1.04 to 1.35]; p ¼ 0.005), and CRUSADE
risk score (HR: 1.01 [95% CI: 1.00 to 1.02]; p ¼ 0.023)
(for every 1-point increase in CRUSADE risk score, the
risk increases 1%) but not other baseline demographic
and clinical characteristics or GRACE score.
CENTRAL ILLUSTRATION Efﬁcacy and Safety Endpoints in Patients Undergoing PCI
Days from First Dose
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Montalescot, G. et al. J Am Coll Cardiol. 2014; 64(24):2563–71.
Pre-treatment with prasugrel (30 mg before PCI and 30 mg at the time of PCI) had no effect on the triple efﬁcacy endpoint
(cardiovascular death, myocardial infarction, or stroke) compared with no pre-treatment with prasugrel (60 mg at the time of PCI).
Pre-treatment with prasugrel showed a 3-fold increase in the incidence of non-coronary artery bypass graft Thrombolysis In Myocardial
Infarction (TIMI) major or minor bleeding compared with no pre-treatment. Patients received a 10 mg dose of prasugrel as daily
maintenance through day 30. Numerical results are shown for 7 days of treatment and 30 days of treatment. CABG ¼ coronary artery
bypass graft; CV ¼ cardiovascular; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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2568ADVERSE EFFECTS. The incidence of TIMI major
bleeding through 7 days from the ﬁrst loading dose
was signiﬁcantly higher with pre-treatment with
prasugrel (Table 2); this was also true for TIMI major
or minor bleeding (Central Illustration, Table 2). There
was a 3-fold increase in non-CABG major bleeding and
a 6-fold increase in non-CABG life-threatening
bleeding events (Table 2). The most common loca-
tions of TIMI major bleeding through 7 days were
vascular access sites (n ¼ 9), gastrointestinal (n ¼ 5),
pericardial (n ¼ 4), and retroperitoneal (n ¼ 4).
The incidence of TIMI minor bleeding events was
also increased with pre-treatment with prasugrel
(28 [2.01%] vs. 9 [0.65%]). Through 30 days, there
were no additional vascular access site or retroperi-
toneal TIMI major bleeds, but there were 4 additional
gastrointestinal bleeds and an additional pericardial
major bleed. Rates of total transfusions were signiﬁ-
cantly higher in patients who received pre-treatment
with prasugrel at 7 and 30 days (Table 2).Rates of TIMI major bleeding were higher in
patients who received pre-treatment with prasugrel
with both radial and femoral access. Through 7 days,
TIMI major bleeding events in patients with radial
access were numerically higher with pre-treatment
with prasugrel (4 vs. 1; HR: 3.82 [95% CI: 0.43 to
34.15]; p ¼ 0.197). Through 7 days, TIMI major or
minor bleeding events in patients with radial access
was also numerically higher with pre-treatment with
prasugrel (7 [1.15%] vs. 2 [0.34%]; HR: 3.35 [95% CI:
0.70 to 16.10]; p ¼ 0.109). Through 7 days, TIMI major
bleeding events in patients with femoral access and
use of a closure device were numerically higher with
pre-treatment with prasugrel (6 vs. 2; p ¼ 0.180).
Through 7 days, TIMI major or minor bleeding events
in patients with femoral access and a closure device
were higher with pre-treatment with prasugrel
(18 [5.84%] vs. 3 [1.03%]; HR: 5.81 [95% CI: 1.71 to
19.7]; p ¼ 0.001). Fourteen of the 18 TIMI major or
minor bleeding locations were at the vascular access
TABLE 2 Bleeding Endpoints Through 7 Days and 30 Days
Pre-Treatment No Pre-Treatment HR (95% CI)* P Value†
7 days (n ¼ 1,394) (n ¼ 1,376)
All CABG or non-CABG TIMI
major bleeding events
(key safety endpoint)
19 (1.4) 7 (0.51) 2.69 (1.13–6.40) 0.02
Non-CABG TIMI major
bleeding events
19 (1.4) 7 (0.51) 2.69 (1.13–6.40) 0.02
Fatal bleeding 0 (0) 0 (0) NE NE
Life-threatening bleeding 12 (0.86) 2 (0.15) 5.93 (1.33–26.5) 0.008
Location of non-CABG TIMI
major bleeding‡
ICH 0 (0) 0 (0) NE NE
Vascular access site 7 (0.50) 2 (0.15) NE NE
GI 2 (0.14) 3 (0.22) NE NE
Hematuria 1 (0.07) 0 (0) NE NE
Pericardial 3 (0.21) 1 (0.07) NE NE
Other§ 5 (0.36) 1 (0.07) NE NE
Non-CABG TIMI major/minor
bleeding
47 (3.4) 16 (1.2) 2.94 (1.67–5.18) <0.001
Total transfusionk 20 (1.4) 7 (0.5) 0.0131
STEEPLE major (non-CABG) 35 (2.5) 14 (1.0) 2.49 (1.34–4.63) 0.003
STEEPLE minor (non-CABG) 48 (3.4) 35 (2.5) 1.36 (0.88–2.10) 0.166
30 days (n ¼ 1,389) (n ¼ 1,372)
All CABG or non-CABG TIMI
major bleeding events
24 (1.7) 9 (0.66) 2.65 (1.23–5.69) 0.010
Non-CABG TIMI major bleeding
events
24 (1.7) 9 (0.66) 2.65 (1.23–5.69) 0.010
Fatal bleeding 2 (0.14) 0 (0) NE NE
Life-threatening bleeding 17 (1.2) 3 (0.22) 5.61 (1.64–19.13) 0.002
Location of non-CABG TIMI
major bleeding‡
ICH 0 (0) 1 (0.07) NE NE
Vascular access site 7 (0.50) 2 (0.15) NE NE
GI 4 (0.29) 5 (0.36) NE NE
Hematuria 1 (0.07) 0 (0) NE NE
Pericardial 4 (0.29) 1 (0.07) NE NE
Other§ 6 (0.44) 1 (0.07) NE NE
Non-CABG TIMI major/minor
bleeding
59 (4.3) 19 (1.4) 3.11 (1.86–5.22) <0.001
Total transfusionk 26 (1.9) 11 (0.8) 0.0145
STEEPLE major (non-CABG) 45 (3.2) 18 (1.3) 2.49 (1.44–4.31) <0.001
STEEPLE minor (non-CABG) 61 (4.4) 46 (3.4) 1.32 (0.90–1.93) 0.157
Values for pre-treatment and no pre-treatment are n (%). *HRs and 2-sided 95% CIs are from a Cox proportional
hazards model with treatment as a ﬁxed effect. †Two-sided p value on the basis of the log-rank test. ‡Partici-
pants experiencing more than 1 bleeding event may be included in more than 1 TIMI bleeding category. Within
each TIMI category, locations are reported for the ﬁrst TIMI bleed in the category. §Other for 7 days included
retroperitoneal, respiratory tract, and unknown. Other for 30 days included retroperitoneal, surgical incision site,
respiratory tract, and unknown. kTransfusion includes any transfusion, fresh frozen plasma, packed red blood
cells, platelets, and whole blood cells. The p value was calculated using chi-square test. Event rates are raw
percents.
CABG ¼ coronary artery bypass graft; GI ¼ gastrointestinal; ICH ¼ intracranial hemorrhage; STEEPLE ¼ Safety
and Efﬁcacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized
Evaluation; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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2569site or retroperitoneal. Through 7 days, TIMI major
bleeding events in patients with femoral access and
without a closure device were numerically higher
with pre-treatment with prasugrel (9 [1.90%] vs.
4 [0.80%]; HR: 2.40 [95% CI: 0.74 to 7.79]; p ¼ 0.132).
TIMI major or minor bleeding events in patients
with femoral access without a closure device were
higher with pre-treatment with prasugrel (22 [4.65%]
vs. 11 [2.20%]; HR: 2.16 [95% CI: 1.05 to 4.45];
p ¼ 0.033). Thirteen of the 22 TIMI major or minor
bleeding events with pre-treatment with prasugrel
were at the vascular access site or retroperitoneal
bleeding. Multivariate analysis for TIMI major
bleeding identiﬁed femoral (vs. radial) access (HR:
3.01 [95% CI: 1.13 to 8.00]; p ¼ 0.027) and treatment
group (HR: 2.77 [95% CI: 1.16 to 6.60]; p ¼ 0.022) as
the 2 strongest independent correlates of bleeding
complications.
DISCUSSION
Patients with NSTEMI who are undergoing PCI theo-
retically represent the ideal population for pre-
treatment with a P2Y12 antagonist because they have
a thrombotic index event, their coronary anatomy is
deﬁned, and they have an indication of coronary
stenting with dual antiplatelet therapy. However, our
study showed that there was no additional beneﬁt
with pre-treatment with prasugrel compared with
administration of prasugrel at the time of PCI to re-
duce the ischemic primary and main secondary end-
points in the NSTEMI population. Moreover, earlier
administration of prasugrel was not associated with
less thrombus burden at the time of the procedure,
less stent thrombosis, or less urgent revascularization
and did not decrease the use of GP inhibitors, which
remained low in this double-blind study. In contrast,
pre-treatment with prasugrel caused a signiﬁcant
excess of major bleeding complications, a risk not
eliminated by radial access or the use of a closure
device after femoral access. Pre-treatment with pra-
sugrel was a strong correlate of major bleeding and
major or minor bleeding independently of other var-
iables, including vascular access.
The concept of pre-treatment with P2Y12 antago-
nists in patients with NSTE-ACS comes from the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent
Events) study, in which patients were managed
conservatively with a further beneﬁt suggested in the
subgroup of 21% of patients who underwent PCI with
or without stent implantation on average 6 days after
randomization (10,11). The PCI meta-analysis, on the
basis of the subsets of 2 randomized studies per-
formed 15 years ago, showed a 22% relative riskreduction of major adverse cardiac events balanced
with a 28% relative increase in major bleeding and no
mortality beneﬁt (5). Therefore, the potential beneﬁt
of pre-treatment with clopidogrel in patients with
NSTE-ACS undergoing PCI is difﬁcult to claim from
these data and even more difﬁcult to extend to
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and invasively managed. The PCI cohort of patients
enrolled in the ACCOAST study was a pre-speciﬁed
subgroup that reﬂects modern practice of manage-
ment of acute coronary syndrome, including early
revascularization, and was larger than the PCI-CURE
(Percutaneous Coronary Intervention in the Clopi-
dogrel in Unstable Angina to Prevent Recurrent
Events) cohort. Indeed, our patients were rapidly
managed in the catheterization laboratory, with large
use of radial access and closure devices; signiﬁcant
numbers of long lesions, left main, and multivessel
stenting; and treatment with a predominance of drug-
eluting stents. Although patients could undergo
angiography up to 48 h from randomization, the
median time to angiography was shorter, which is
similar to what has been observed in contemporary
studies of acute coronary syndrome (12–16).
The ACCOAST investigators noted prospectively
the presence of thrombus on angiography because
they were blinded to study drug, and 21% of patients
were found to have an intracoronary thrombus. Visu-
ally, there was no patient characteristic, including the
GRACE score or any coronary characteristic, that was
predictive of the presence of thrombus in these pa-
tients who had a signiﬁcant increase in troponin levels
at admission. Pre-treatment with prasugrel did not
reduce the presence of thrombus before the start of the
PCI procedure and did not reduce the thrombotic
complications during the procedure. However, the
angiographic presence of thrombus drove the use of
GP inhibitors (8-fold increase) and was associated with
more frequent urgent revascularization (3-fold in-
crease), more frequent myocardial infarctions (50%
increase), and altogether a 2.5-fold increase in the
incidence of the primary endpoint.
The multivariate analysis of the primary efﬁcacy
outcome concludes that lesion- or stent-related
characteristics predict outcome, and the presence of
thrombus was the stronger variable in this model. The
ACCOAST study reinforces the role of angiography to
diagnose NSTEMI, indicate the need for PCI, and
avoid pre-treatment with prasugrel when it is not
required. The ACCOAST-PCI study shows that there is
no downside in waiting to provide prasugrel until
after coronary angiography in patients who will need
dual antiplatelet therapy for stenting. The angiogram
provides additional information on the risk of the
procedure and the prognosis for these patients.
Although PCI was performed in patients who had an
increase in troponin levels, with frequent long or
multiple lesions and a high rate of thrombus-
containing lesions, the rate of GP IIb/IIIa inhibitoruse remained low and stent thrombosis was infre-
quent in both arms. This suggests that the strategy of
prasugrel loading after angiography is not only safer
but also effective in this population.
STUDY LIMITATIONS. Although our study was pre-
speciﬁed, its limitations include the fact that the
original effects of randomization at entry into the trial
are no longer present for the cohort of patients who
have undergone PCI. To alleviate this issue, we pre-
sented the baseline characteristics of the patients,
which were well balanced between the 2 groups.
Moreover, it would be practically impossible to
perform a randomized study of pre-treatment only in
patients undergoing PCI, knowing that more than 90%
of patients undergo ad-hoc PCI (in the same setting as
angiography). Another limitation is the time frame
from randomization to PCI (2 to 48 h), and our results
apply only to patients with rapid access to the cathe-
terization laboratory. The negative results from pre-
treatment with prasugrel in the NSTEMI population
in the ACCOAST study cannot be applied to the ST-
segment elevation myocardial infarction population.
The ATLANTIC (A 30 Day Study to Evaluate Efﬁcacy
and Safety of Pre-hospital vs. In-hospital Initiation of
Ticagrelor Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention [PCI]) trial
(NCT01347580) will provide answers to the question
of the use of pre-hospital treatment with a P2Y12 in-
hibitor in the ST-segment elevation myocardial
infarction population (17). Finally, whether our con-
clusions can be extended to other oral P2Y12 antago-
nists will remain a matter of debate because no similar
study has been performed in the same conditions with
ticagrelor or clopidogrel. Considering the recent
reappraisal of pre-treatment with clopidogrel, we
advise caution with pre-treatment.
CONCLUSIONS
In patients with NSTEMI, our data support deferring a
loading dose of prasugrel until a decision is made
about revascularization. This strategy allows ﬂexi-
bility in the management of patients by providing
prasugrel, with its rapid onset of action, to patients
who proceed to PCI without risking bleeding compli-
cations in patients who do not proceed to PCI.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients
with NSTEMI and a thrombus burden face increased rates
of adverse events compared with those without a
thrombus burden.
COMPETENCY IN PATIENT CARE: Patients with
NSTEMI face an increased risk of bleeding when
pre-treated with a rapid-onset P2Y12 platelet inhibitor.
TRANSLATIONAL OUTLOOK: These results support
delaying a loading dose of prasugrel until a decision is
made about revascularization because of increases in all
non-CABG major and life-threatening TIMI bleeding
events without reduction of ischemic events associated
with pre-treatment with prasugrel in patients with
NSTEMI.
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